CLINICAL TRIALS PROFILE FOR SECNIDAZOLE

All Clinical Trials for secnidazole

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01019083 ↗	Studies of Immune Responses to Orally Administered Vaccines in Developing Country	Completed	Göteborg University	Phase 1/Phase 2	2008-02-01	The efficacy and immunogenicity of enteric vaccines have generally been found to be lower in children in the developed than in the developing countries. This has been observed with vaccines against cholera rotavirus, ETEC and typhoid vaccines. There are a number of factors that may contribute to such differences in vaccine "take rates" in children, e.g. breast feeding and nutritional status of the children might influence their immunogenicity and efficacy. Thus, breast feeding of newborn and young infants may adversely influence the immune response to vaccination, which might have more pronounced effect in developing than in developed countries. Breastfeeding has also been shown to interfere with the serum immune responses to rotavirus vaccine although this effect could be overcome by administering three rather than one dose of the oral rotavirus vaccine. Our recent study of Dukoral in Bangladeshi children aged 18 months or younger has shown that the response rates and the magnitude of responses improved when breast milk was temporarily withheld . Thus, administration of vaccines may have to be adjusted when given to breast fed children. Another factor that may affect the immunogenicity is the effect of zinc. Previous studies have shown that zinc enhances the immune response to cholera vaccine in participants > 2 years of age , a recent study also observed a similar effect in infants. In this research project, we plan to study a number of different factors that might influence the immunogenicity of the two licensed oral model vaccines, specifically the inactivated killed oral cholera vaccine, Dukoral, and the live oral typhoid vaccine, Ty21a. We will also identify strategies that might improve the immunogenicity of the vaccines. The main objective of our study is to identify immunization regimens that may improve the immunogenicity of the vaccines in young children, which could be subsequently in field trials in Bangladesh and other developing countries. Specifically, we will determine if: (i) interventions identified to enhance immune responses to Dukoral, including zinc supplementation, could also enhance the immune responses to Ty21a; (ii) these two vaccines are able to induce both acute and memory B and T cell responses, (iii) treatment with antiparasitic drugs prior to immunization could modulate the immune responses to cholera and typhoid vaccines; and (iv) examine if arsenic exerts a suppressive effect on the immunogenicity of these vaccines.
NCT01019083 ↗	Studies of Immune Responses to Orally Administered Vaccines in Developing Country	Completed	International Centre for Diarrhoeal Disease Research, Bangladesh	Phase 1/Phase 2	2008-02-01	The efficacy and immunogenicity of enteric vaccines have generally been found to be lower in children in the developed than in the developing countries. This has been observed with vaccines against cholera rotavirus, ETEC and typhoid vaccines. There are a number of factors that may contribute to such differences in vaccine "take rates" in children, e.g. breast feeding and nutritional status of the children might influence their immunogenicity and efficacy. Thus, breast feeding of newborn and young infants may adversely influence the immune response to vaccination, which might have more pronounced effect in developing than in developed countries. Breastfeeding has also been shown to interfere with the serum immune responses to rotavirus vaccine although this effect could be overcome by administering three rather than one dose of the oral rotavirus vaccine. Our recent study of Dukoral in Bangladeshi children aged 18 months or younger has shown that the response rates and the magnitude of responses improved when breast milk was temporarily withheld . Thus, administration of vaccines may have to be adjusted when given to breast fed children. Another factor that may affect the immunogenicity is the effect of zinc. Previous studies have shown that zinc enhances the immune response to cholera vaccine in participants > 2 years of age , a recent study also observed a similar effect in infants. In this research project, we plan to study a number of different factors that might influence the immunogenicity of the two licensed oral model vaccines, specifically the inactivated killed oral cholera vaccine, Dukoral, and the live oral typhoid vaccine, Ty21a. We will also identify strategies that might improve the immunogenicity of the vaccines. The main objective of our study is to identify immunization regimens that may improve the immunogenicity of the vaccines in young children, which could be subsequently in field trials in Bangladesh and other developing countries. Specifically, we will determine if: (i) interventions identified to enhance immune responses to Dukoral, including zinc supplementation, could also enhance the immune responses to Ty21a; (ii) these two vaccines are able to induce both acute and memory B and T cell responses, (iii) treatment with antiparasitic drugs prior to immunization could modulate the immune responses to cholera and typhoid vaccines; and (iv) examine if arsenic exerts a suppressive effect on the immunogenicity of these vaccines.
NCT02111629 ↗	Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge	Completed	Universidad Nacional de Colombia	Phase 3	2012-05-01	Genital tract infections (GTIs) have increased in the past decade and there is an association between sexually transmitted infections (STIs) and other infections like bacterial vaginosis (BV), with the HIV transmission. BV and Candida are the most common causes of vaginal infections in symptomatic women, the prevalence of BV being 22-50% and the prevalence of Candida 17-39%. In an effort to reduce the transmission of GTIs, the World Health Organization (WHO) proposed a syndromic diagnostic approach as a low cost alternative in places with no access to laboratory diagnostic tests. Justification. In patients with syndrome of vaginal discharge, an effective treatment against Candida albicans, Trichomonas vaginalis, and bacterial vaginosis is adviced, therefore, for syndromic management of symptomatic vaginal discharge the combination of fluconazole and secnidazole could be used. No studies evaluating this combination were found in the literature reviewed. Objectives: To describe the safety and the clinical and microbiological efficacy of a single oral dose of a combined treatment with secnidazole + fluconazole for the syndromic management of symptomatic vaginal discharge. Methods: Design: open label, uncontrolled clinical trial to estimate clinical efficacy and safety of the combination of fluconazole and secnidazole for the treatment of symptomatic vaginal discharge. The participants will be sexually active women with lower genital tract symptoms (leukorrhea, itching, burning, pain, foul-smelling vaginal discharge, or urethral symptoms) compatible with symptomatic vaginal discharge syndrome. The study will be conducted in an outpatient service of a hospital in Bogota, Colombia. Given the descriptive character of the study, no a priori hypothesis is considered. A consecutive convenience sample size of 100 symptomatic patients is calculated. The statistical analysis will be performed with STATA 11.0 software (College Station, Texas, USA). Simple and relative frequencies and measures of central tendency and dispersion appropriate for the distribution of the variables will be calculated. The study has been submitted and approved by the Ethics Committee of the Faculty of Medicine of the National University of Colombia and the Institutional Review Board of the participating institution. All women must sign a written informed consent form agreeing to voluntarily participate in the study.
NCT02147899 ↗	A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis	Completed	Symbiomix Therapeutics	Phase 2	2014-05-01	The purpose of this research study is to test the safety and effectiveness of the oral investigational new drug, SYM-1219, for the treatment of bacterial vaginosis.
NCT02452866 ↗	Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219	Completed	Symbiomix Therapeutics	Phase 3	2015-06-01	This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent girls with bacterial vaginosis.
NCT03935217 ↗	A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis	Completed	Lupin Research Inc	Phase 3	2019-04-23	This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.

Clinical Trial Conditions for secnidazole

Condition Name

Condition Name for secnidazole
Intervention	Trials
Bacterial Vaginosis	2
Bacterial Vaginitis	1
Bacterial Vaginoses	1
Cholera	1

Condition MeSH

Condition MeSH for secnidazole
Intervention	Trials
Vaginosis, Bacterial	5
Vaginal Diseases	4
Vaginal Discharge	1
Typhoid Fever	1

Clinical Trial Locations for secnidazole

Trials by Country

Trials by Country for secnidazole
Location	Trials
United States	54
Colombia	1
Bangladesh	1

Trials by US State

Trials by US State for secnidazole
Location	Trials
Florida	5
Tennessee	4
Alabama	4
Virginia	3
Texas	3

Clinical Trial Progress for secnidazole

Clinical Trial Phase

Clinical Trial Phase for secnidazole
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	1
Phase 3	3

Clinical Trial Status

Clinical Trial Status for secnidazole
Clinical Trial Phase	Trials
Completed	6
RECRUITING	2

Clinical Trial Sponsors for secnidazole

Sponsor Name

Sponsor Name for secnidazole
Sponsor	Trials
Symbiomix Therapeutics	2
Lupin Research Inc	2
Lupin Pharmaceuticals, Inc.	1

Sponsor Type

Sponsor Type for secnidazole
Sponsor	Trials
Other	7
Industry	5
UNKNOWN	1

Last updated: July 28, 2026

Secnidazole Clinical Trials Update, Market Analysis, and Launch Projections

Secnidazole remains a small-molecule anti-infective with limited late-stage trial density globally. Commercial outlook depends on geography-specific approvals, competitive pressure from metronidazole and tinidazole, and payer access for 1-dose or short-course regimens. Patent and regulatory timelines drive generics and formulation competition more than new clinical differentiation.

What is secnidazole approved for and where is it marketed?

Secnidazole is used for protozoal and anaerobic bacterial infections, with common label indications tied to:

• Bacterial vaginosis (BV)
• Trichomoniasis
• Giardiasis/amoebiasis in some jurisdictions
• Anaerobic infections where nitroimidazoles are standard of care

Key branded vs generic patterns

Secnidazole tends to be sold in single-dose or short-course presentations depending on country. Market structure is typically:

• Branded originator in select geographies
• Multi-generic environment where patents have expired or where regulatory barriers are low
• Competition from metronidazole formulations (oral, vaginal) and tinidazole short-course regimens

Regulatory posture

In many markets, secnidazole is positioned as a nitroimidazole alternative with a regimen advantage (adherence). That drives uptake where prescribers respond to shorter courses.

Clinical implication for trials: new studies typically target adherence, comparable efficacy, safety, and local standard-of-care comparisons rather than novel mechanisms.

What are the latest secnidazole clinical trials and how do they update the pipeline?

Secnidazole’s clinical trial footprint is usually dominated by:

• Bioequivalence (BE) studies for generics and reformulations
• Open-label or comparator trials in regionally relevant indications (BV, trichomoniasis)
• Smaller investigator-led studies for tolerability and regimen equivalence

Where do trials usually concentrate

High-frequency trial locations for nitroimidazole generics and regimen studies include:

• Emerging markets with high BV and STI burden and large private-sector prescribing
• Countries where secnidazole is already registered, which supports BE-driven entry

What a “clinical update” means for secnidazole specifically

For secnidazole, “pipeline value” rarely comes from Phase 3 novelty. The practical update signal is:

• BE/PK submissions that precede generic approvals
• Local Phase 3/PK bridging that unlocks new pack sizes and higher volume use
• Formulation development (eg, granules or taste-masked pediatric options) when local demand supports it

Bottom-line trial read-across

• If the trial activity is primarily BE, it is a competitive entry indicator, not a differentiation indicator.
• If Phase 3 comparator trials are reported for a region, it tends to support label expansion or stronger prescribing confidence in that jurisdiction.

How does secnidazole’s clinical evidence compare with metronidazole and tinidazole?

Secnidazole competes clinically on:

• Adherence (often single-dose or short-course)
• Comparable efficacy to other nitroimidazoles for targeted infections
• Acceptability where regimen simplicity affects outcomes

Key differentiators used by brands

• Single-dose convenience for BV or trichomoniasis-like indications in some markets
• Short treatment windows for anaerobic infection adjuncts, depending on local label

Competitive displacement risk

Metronidazole has broad access and longstanding guidelines. Tinidazole is also used in short-course regimens in multiple countries. That means secnidazole typically faces:

• Lower pricing power unless branded differentiation persists
• Margin pressure when generics cluster around BE entry

When does secnidazole lose exclusivity and what patent expiry drives generic entry risk?

Secnidazole is a mature nitroimidazole with extensive history of use. For most markets, exclusivity and formulation IP are typically either:

• Already expired, or
• Concentrated in specific country-level patents on process, polymorphs, or formulations rather than drug substance.

Business consequence: generic entry risk for secnidazole is usually driven by:

• Local registration timelines (dossiers, BE requirements, agency review capacity)
• Existing generic portfolio breadth
• Any remaining formulation IP tied to specific dosage forms

What to watch for in Orange Book-style analogs and local registries

Where applicable, investors and litigators track:

• Method-of-use listings (if any remain in that jurisdiction)
• Formulation/process patents attached to brand packaging and dosage strengths
• Regulatory exclusivity blocks only when tied to specific new NDA/MAH filings

What patent estate protects secnidazole and its key formulations?

For a mature molecule like secnidazole, patent protection typically fragments into:

• Drug substance patents (often expired globally)
• Formulation patents (granules, tablets, taste masking, dissolution profile)
• Manufacturing process patents (impurity profile control, crystallization)

Practical impact on product strategy

• Brands defend with new formulations or new pack/strength strategies rather than new MOA.
• Generics defend through BE and manufacturing process choices that avoid process-specific claims.

What generic entry risks exist for secnidazole by indication and dosage form?

Generic risk is most acute for:

• Tablet/capsule strengths where BE is straightforward
• Granules or pediatric-friendly formats if taste-masking claims are not enforceable locally
• Short-course regimens where prescribers accept switching

Packaging and dose form as a barrier

Where a brand sells:

• A single-dose pack, and
• The manufacturing uses a distinct formulation platform, generic entry may be slower in that specific SKU due to formulation differentiation, even if the molecule is off-patent.

What is the Orange Book status of secnidazole?

Secnidazole is not a US-centric blockbuster in modern times; the US regulatory record depends on current listed products, which may be generic-led. If there are Orange Book listings, they tend to be:

• Outdated or limited to legacy patents
• Non-blocking once drug substance exclusivity ends

Market implication: in the US, secnidazole availability often reflects a mature generic marketplace rather than patent-driven restriction.

Which companies are most active in secnidazole’s competitive landscape?

Competitive sets for mature nitroimidazoles usually include:

• Large Indian and international generic manufacturers
• Regional branded players in geographies where secnidazole retains brand share via regimen convenience

How to interpret “activity”

For secnidazole, the most actionable competitive signals are:

• New BE filings tied to specific strengths and pack sizes
• Product launches in markets with higher STI/BV prescribing and where single-dose adoption exists
• Marketing spend that leverages adherence messaging

How large is the secnidazole market and what are the demand drivers?

Secnidazole demand is driven by:

• BV and STI burden in women’s health
• Acceptance of nitroimidazole class therapy
• Preference for short-course adherence where culturally and clinically relevant

Market size framing

Public market sizes for secnidazole are typically reported within broader nitroimidazole or anti-anaerobic segments. Practical sizing relies on:

• Count of approved strengths and dosage forms in each geography
• Typical treatment course consumption (single-dose vs multi-day)
• Generic penetration and price erosion speed

Unit economics

• Single-dose therapy can support similar patient-level spend even as tablet prices erode, if adherence reduces loss of follow-up.
• Payer pressure drives rapid discounting in markets where formularies favor lowest net price.

What pricing and payer dynamics are shaping secnidazole forecasts?

Expect:

• Falling ex-manufacturer prices with generic clustering
• Stable-to-modest revenue resilience where branded single-dose pack maintains differentiation
• Margin volatility due to procurement model changes in institutional purchasing

Procurement behavior

In women’s health and STI categories, procurement often rewards:

• Lowest cost per course
• Reliability of supply
• Pack form factor that aligns with clinic workflows

What is the revenue projection for secnidazole through 2030?

A reasonable forward view for a mature, off-patent-like molecule is:

• Flat to low single-digit CAGR in global revenues in nominal terms
• Volume growth tied to infection burden and access improvements
• Price erosion as generic competition persists

Projection logic by scenario

• Base case: modest global growth offset by ongoing price compression
• Bull case: stronger uptake of single-dose regimens in high-burden geographies plus limited formulation differentiation defenses
• Bear case: accelerated generic entry in additional markets and deeper discounting by large distributors

How will secnidazole competitive pressure from metronidazole affect market share?

Metronidazole has:

• Broader regimen options (oral and topical)
• More guideline familiarity in multiple regions
• Stronger supply chains in many countries

That creates share pressure for secnidazole unless secnidazole’s regimen simplicity is retained by prescribers and patients.

Share shift mechanics

• When formulary restrictions tighten, lower-cost generics dominate.
• When adherence programs exist, shorter-course nitroimidazoles can gain relative share.

What manufacturing/IP barriers could slow secnidazole generic entry?

Barriers are typically formulation or process-specific:

• Impurity profile control
• Crystallization and polymorph control where claimed
• Dissolution profile and bioavailability sensitivity
• Supply chain quality and regulatory inspection outcomes

For mature molecules, the barrier is rarely “hard IP” and more often “regulatory and manufacturing execution.”

What formulation patents matter most for secnidazole?

In many markets, formulation patents matter most for:

• Bioavailability-improved forms
• Stability improvements (shelf life, moisture handling)
• Taste-masking and pediatric acceptability
• Granule/tablet robustness that supports consistent BE performance

These patents can block direct generic “drop-in” substitutions even when drug substance is unrestricted.

What regulatory pathway changes could influence secnidazole availability?

Key influences typically include:

• BE study requirements evolving toward stricter guidance
• GMP inspection outcomes affecting approval timelines
• Labeling or safety updates changing patient usage patterns

Regulators generally treat secnidazole as a mature anti-infective; change drivers are mostly procedural rather than mechanistic.

Key takeaways

• Secnidazole is a mature nitroimidazole with limited likelihood of a major late-stage differentiation breakthrough.
• “Clinical updates” for secnidazole largely translate into BE-driven competitive entry and formulation SKU expansion rather than transformative efficacy or safety changes.
• Market growth is constrained by generic pricing dynamics. Revenue outlook through 2030 is likely flat to modest growth globally, with volume growth only partially offset by price erosion.
• Competitive forecasting should track country-level approvals, SKU launches (strength/pack form), and local formulation/process differentiation more than patenting of the underlying molecule.

FAQs

1) Does secnidazole have ongoing Phase 3 trials for bacterial vaginosis?

The most frequent activity for secnidazole in mature indications tends to be comparator-lite or BE studies rather than large global Phase 3 programs, which is consistent with a mature competitive landscape.

2) Are there pediatric formulations of secnidazole that could expand market access?

Where pediatric-friendly dosage forms exist (or new taste-masked formats launch), they can shift prescribing in markets with pediatric adherence barriers.

3) What is the biggest risk to secnidazole revenue from generics?

Price compression from rapid generic clustering across multiple strengths and pack sizes, particularly where formulary procurement favors lowest cost per course.

4) Can new secnidazole formulations extend product life?

Yes when formulation IP and regulatory strategy protect specific dosage forms or bioavailability characteristics, but defense is usually geographic and SKU-specific.

5) How should investors benchmark secnidazole pipeline value versus other nitroimidazoles?

Benchmark on regional BE and approval cadence, SKU expansion, and procurement outcomes, not on novel MOA development, which is uncommon for this molecule.

References

No sources were provided in the prompt, and no reliable, citable dataset (eg, FDA Orange Book listings, EMA EPARs, ClinicalTrials.gov trial records, or company filings) is included in the conversation.